We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™
News

Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™

Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™
News

Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Licensing of the GS Gene Expression System™ expands OBT’s access to world-class technologies for its maturing pipeline of therapeutic antibodies in oncology, and demonstrates its commitment to strengthening both antibody production and preclinical capabilities.

“We are delighted to have access to Lonza’s GS Gene Expression System™ as an addition to our technology portfolio”, commented Tom Boone, who recently joined OBT as Senior Vice President, Protein Sciences following 28 years at Amgen.

Boone continued, “The speed and ease of use of the GS System™ will aid the rapid selection of high-producing cell lines and accelerate the production and development of our most promising anticancer agents.”

“We are proud to have our GS Gene Expression System™ contribute to Oxford BioTherapeutics innovation in cancer research,” said Janet White, Head of Development Services.

White continued, “We look forward to supporting OBT’s efforts to expand and develop its pipeline of promising new oncology drugs.”

OBT has a broad pipeline of preclinical antibody programs directed to novel cancer targets that it has identified using its OGAP® proteomic database.

Advertisement